# Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy

> **NCT07240844** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Seoul St. Mary's Hospital** · enrollment: 68 (estimated)

## Conditions studied

- Amyloid Cardiomyopathy

## Interventions

- **DRUG:** Enavogliflozin 0.3mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07240844
- **Lead sponsor:** Seoul St. Mary's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-24
- **Primary completion:** 2027-04-29
- **Final completion:** 2027-05-31
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07240844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07240844, "Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07240844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*